Any 0 3 0 3 O
line 4 8 4 8 O
of 9 11 9 11 O
prior 12 17 12 17 B-treatment
therapy 18 25 18 25 I-treatment

Calculated 0 10 26 36 B-clinical_variable
creatinine 11 21 37 47 I-clinical_variable
clearance 22 31 48 57 I-clinical_variable
must 32 36 58 62 O
be 37 39 63 65 O
> 40 41 66 67 O
= 41 42 67 68 O
30 43 45 69 71 B-lower_bound
mL 46 48 72 74 I-lower_bound
/ 48 49 74 75 I-lower_bound
minute 49 55 75 81 I-lower_bound

Eastern 0 7 82 89 B-clinical_variable
Cooperative 8 19 90 101 I-clinical_variable
Oncology 20 28 102 110 I-clinical_variable
Group 29 34 111 116 I-clinical_variable
( 35 36 117 118 I-clinical_variable
ECOG 36 40 118 122 I-clinical_variable
) 40 41 122 123 I-clinical_variable
performance 42 53 124 135 I-clinical_variable
status 54 60 136 142 I-clinical_variable
0 61 62 143 144 B-lower_bound
- 62 63 144 145 O
2 63 64 145 146 B-upper_bound

Have 0 4 147 151 O
unresectable 5 17 152 164 O
malignant 18 27 165 174 B-cancer
mesothelioma 28 40 175 187 I-cancer
( 41 42 188 189 O
any 42 45 189 192 O
histology 46 55 193 202 O
) 55 56 202 203 O

Hemoglobin 0 10 204 214 B-clinical_variable
( 11 12 215 216 I-clinical_variable
Hgb 12 15 216 219 I-clinical_variable
) 15 16 219 220 I-clinical_variable
> 17 18 221 222 O
8.5 19 22 223 226 B-lower_bound
g 23 24 227 228 I-lower_bound
/ 24 25 228 229 I-lower_bound
dL 25 27 229 231 I-lower_bound

Known 0 5 232 237 O
hypersensitivity 6 22 238 254 O
to 23 25 255 257 O
brentuximab 26 37 258 269 B-allergy_name
vedotin 38 45 270 277 I-allergy_name
components 46 56 278 288 I-allergy_name

Male 0 4 289 293 B-gender
subject 5 12 294 301 I-gender

Platelets 0 9 302 311 B-clinical_variable
> 10 11 312 313 O
100,000 12 19 314 321 B-lower_bound
/ 19 20 321 322 I-lower_bound
mm^3 20 24 322 326 I-lower_bound

Positive 0 8 327 335 B-cancer
CD30 9 13 336 340 I-cancer
+ 13 14 340 341 O
immunohistochemical 15 34 342 361 O
expression 35 45 362 372 O

Radiation 0 9 373 382 B-treatment
therapy 10 17 383 390 I-treatment
to 18 20 391 393 O
more 21 25 394 398 O
than 26 30 399 403 O
25 31 33 404 406 B-lower_bound
% 33 34 406 407 I-lower_bound
of 35 37 408 410 O
the 38 41 411 414 O
bone 42 46 415 419 O
marrow 47 53 420 426 O

Serious 0 7 427 434 B-chronic_disease
medical 8 15 435 442 I-chronic_disease
or 16 18 443 445 I-chronic_disease
psychiatric 19 30 446 457 I-chronic_disease
illness 31 38 458 465 I-chronic_disease
likely 39 45 466 472 O
to 46 48 473 475 O
interfere 49 58 476 485 O
with 59 63 486 490 O
participation 64 77 491 504 O
in 78 80 505 507 O
this 81 85 508 512 O
clinical 86 94 513 521 O
study 95 100 522 527 O

Total 0 5 528 533 O
bilirubin 6 15 534 543 B-clinical_variable
= 16 17 544 545 O
< 17 18 545 546 O
1.5 19 22 547 550 B-upper_bound
x 23 24 551 552 I-upper_bound
upper 25 30 553 558 I-upper_bound
limit 31 36 559 564 I-upper_bound
of 37 39 565 567 I-upper_bound
normal 40 46 568 574 I-upper_bound
( 47 48 575 576 I-upper_bound
ULN 48 51 576 579 I-upper_bound
) 51 52 579 580 I-upper_bound

completely 0 10 581 591 O
abstain 11 18 592 599 O
from 19 23 600 604 O
heterosexual 24 36 605 617 O
intercourse 37 48 618 629 O
during 49 55 630 636 O
the 56 59 637 640 O
entire 60 66 641 647 O
study 67 72 648 653 O
treatment 73 82 654 663 O
period 83 89 664 670 O
through 90 97 671 678 O
6 98 99 679 680 B-upper_bound
months 100 106 681 687 I-upper_bound
after 107 112 688 693 O
the 113 116 694 697 O
last 117 121 698 702 O
dose 122 126 703 707 O
of 127 129 708 710 O
brentuximab 130 141 711 722 B-treatment
vedotin 142 149 723 730 I-treatment

confirmation 0 12 731 743 O
that 13 17 744 748 O
the 18 21 749 752 O
subject 22 29 753 760 O
is 30 32 761 763 O
not 33 36 764 767 B-pregnancy
pregnant 37 45 768 776 I-pregnancy
must 46 50 777 781 O
be 51 53 782 784 O
established 54 65 785 796 O
by 66 68 797 799 O
a 69 70 800 801 O
negative 71 79 802 810 B-pregnancy
serum 80 85 811 816 I-pregnancy
beta 86 90 817 821 I-pregnancy
- 90 91 821 822 I-pregnancy
human 91 96 822 827 I-pregnancy
chorionic 97 106 828 837 I-pregnancy
gonadotropin 107 119 838 850 I-pregnancy
( 120 121 851 852 I-pregnancy
B 121 122 852 853 I-pregnancy
- 122 123 853 854 I-pregnancy
hCG 123 126 854 857 I-pregnancy
) 126 127 857 858 I-pregnancy
pregnancy 128 137 859 868 I-pregnancy
test 138 142 869 873 O
result 143 149 874 880 O
obtained 150 158 881 889 O
during 159 165 890 896 O
screening 166 175 897 906 O

cured 0 5 907 912 O
of 6 8 913 915 O
a 9 10 916 917 O
skin 11 15 918 922 B-cancer
cancer 16 22 923 929 I-cancer

even 0 4 930 934 O
if 5 7 935 937 O
surgically 8 18 938 948 O
sterilized 19 29 949 959 O
( 30 31 960 961 O
i.e. 31 35 961 965 O
, 35 36 965 966 O
status 37 43 967 973 O
postvasectomy 44 57 974 987 O
) 57 58 987 988 O
, 58 59 988 989 O
agrees 60 66 990 996 B-contraception_consent
to 67 69 997 999 I-contraception_consent
use 70 73 1000 1003 I-contraception_consent
an 74 76 1004 1006 I-contraception_consent
acceptable 77 87 1007 1017 I-contraception_consent
barrier 88 95 1018 1025 I-contraception_consent
method 96 102 1026 1032 I-contraception_consent
for 103 106 1033 1036 I-contraception_consent
contraception 107 120 1037 1050 I-contraception_consent
( 121 122 1051 1052 O
condom 122 128 1052 1058 B-contraception_consent
with 129 133 1059 1063 I-contraception_consent
a 134 135 1064 1065 I-contraception_consent
spermicidal 136 147 1066 1077 I-contraception_consent
agent 148 153 1078 1083 I-contraception_consent
) 153 154 1083 1084 O

examinations 0 12 1085 1097 O
for 13 16 1098 1101 O
assessment 17 27 1102 1112 O
of 28 30 1113 1115 O
measurable 31 41 1116 1126 O
disease 42 49 1127 1134 O
must 50 54 1135 1139 O
have 55 59 1140 1144 O
been 60 64 1145 1149 O
completed 65 74 1150 1159 O
within 75 81 1160 1166 O
28 82 84 1167 1169 B-upper_bound
days 85 89 1170 1174 I-upper_bound
prior 90 95 1175 1180 I-upper_bound
to 96 98 1181 1183 O
registration 99 111 1184 1196 O

no 0 2 1197 1199 O
prior 3 8 1200 1205 O
hematologic 9 20 1206 1217 B-cancer
malignancy 21 31 1218 1228 I-cancer
within 32 38 1229 1235 O
3 39 40 1236 1237 B-upper_bound
years 41 46 1238 1243 I-upper_bound

stage 0 5 1244 1249 B-lower_bound
I 6 7 1250 1251 I-lower_bound
- 7 8 1251 1252 O
III 8 11 1252 1255 B-upper_bound
solid 12 17 1256 1261 B-cancer
tumor 18 23 1262 1267 I-cancer

whole 0 5 1268 1273 B-treatment
pelvic 6 12 1274 1280 I-treatment
radiation 13 22 1281 1290 I-treatment
is 23 25 1291 1293 O
considered 26 36 1294 1304 O
to 37 39 1305 1307 O
be 40 42 1308 1310 O
over 43 47 1311 1315 O
25 48 50 1316 1318 B-lower_bound
% 50 51 1318 1319 I-lower_bound

willing 0 7 1320 1327 B-contraception_consent
to 8 10 1328 1330 I-contraception_consent
use 11 14 1331 1334 I-contraception_consent
an 15 17 1335 1337 I-contraception_consent
acceptable 18 28 1338 1348 I-contraception_consent
method 29 35 1349 1355 I-contraception_consent
of 36 38 1356 1358 I-contraception_consent
birth 39 44 1359 1364 I-contraception_consent
control 45 52 1365 1372 I-contraception_consent
( 53 54 1373 1374 O
i.e. 54 58 1374 1378 O
, 58 59 1378 1379 O
a 60 61 1380 1381 O
hormonal 62 70 1382 1390 B-contraception_consent
contraceptive 71 84 1391 1404 I-contraception_consent
, 84 85 1404 1405 O
intra 86 91 1406 1411 B-contraception_consent
- 91 92 1411 1412 I-contraception_consent
uterine 92 99 1412 1419 I-contraception_consent
device 100 106 1420 1426 I-contraception_consent
, 106 107 1426 1427 O
diaphragm 108 117 1428 1437 B-contraception_consent
with 118 122 1438 1442 I-contraception_consent
spermicide 123 133 1443 1453 I-contraception_consent
, 133 134 1453 1454 O
condom 135 141 1455 1461 B-contraception_consent
with 142 146 1462 1466 I-contraception_consent
spermicide 147 157 1467 1477 I-contraception_consent
, 157 158 1477 1478 O
or 159 161 1479 1481 O
abstinence 162 172 1482 1492 B-contraception_consent
) 172 173 1492 1493 O
for 174 177 1494 1497 O
the 178 181 1498 1501 O
duration 182 190 1502 1510 O
of 191 193 1511 1513 O
the 194 197 1514 1517 O
study 198 203 1518 1523 O
and 204 207 1524 1527 O
at 208 210 1528 1530 O
least 211 216 1531 1536 O
6 217 218 1537 1538 B-lower_bound
months 219 225 1539 1545 I-lower_bound
after 226 231 1546 1551 O
the 232 235 1552 1555 O
last 236 240 1556 1560 O
dose 241 245 1561 1565 O
of 246 248 1566 1568 O
brentuximab 249 260 1569 1580 B-treatment
vedotin 261 268 1581 1588 I-treatment

